Company profile GLMD

Galmed Pharmaceuticals Ltd
galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis,... or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash. Show More
Quarter analysis & expected interestLast update: February 09 2024 06:29:42.

After 39 days of this quarter the interest is at 161.0. Based on that we can calculate that during remaining 52 days it will total up to 376.0.
Galmed Pharmaceuticals expected interest is significantly higher compared to previous quarter (+84.3%) and same quarter last year (+735.6%).

YearQ1Q2Q3Q4
201973
233
219.2% QoQ
285
22.3% QoQ
206
-27.7% QoQ
2020 137
87.7% YoY -33.5% QoQ
60
-74.2% YoY -56.2% QoQ
43
-84.9% YoY -28.3% QoQ
122
-40.8% YoY 183.7% QoQ
2021 197
43.8% YoY 61.5% QoQ
156
160.0% YoY -20.8% QoQ
158
267.4% YoY 1.3% QoQ
177
45.1% YoY 12.0% QoQ
2022 209
6.1% YoY 18.1% QoQ
151
-3.2% YoY -27.8% QoQ
86
-45.6% YoY -43.0% QoQ
88
-50.3% YoY 2.3% QoQ
2023 45
-78.5% YoY -48.9% QoQ
146
-3.3% YoY 224.4% QoQ
144
67.4% YoY -1.4% QoQ
204
131.8% YoY 41.7% QoQ
2024 161
257.8% YoY -21.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Galmed Pharmaceuticals search interestLast update: February 09 2024 06:29:41.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 06:29:43.

The average 5 years interest of Galmed Pharmaceuticals was 11.8 per week.
The last year interest of Galmed Pharmaceuticals compared to the last 5 years has changed by 10.68%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -21.14%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 06:29:46.

After 39 days of this quarter the interest is at 31.0. Based on that we can calculate that during remaining 52 days it will total up to 72.0.
Aramchol expected interest is significantly lower compared to same quarter last year (-47.8%) but similar to previous quarter.

YearQ1Q2Q3Q4
201970
195
178.6% QoQ
0
-100.0% QoQ
35
inf% QoQ
2020 119
70.0% YoY 240.0% QoQ
157
-19.5% YoY 31.9% QoQ
121
inf% YoY -22.9% QoQ
0
-100.0% YoY -100.0% QoQ
2021 33
-72.3% YoY inf% QoQ
170
8.3% YoY 415.2% QoQ
93
-23.1% YoY -45.3% QoQ
64
inf% YoY -31.2% QoQ
2022 119
260.6% YoY 85.9% QoQ
190
11.8% YoY 59.7% QoQ
81
-12.9% YoY -57.4% QoQ
206
221.9% YoY 154.3% QoQ
2023 138
16.0% YoY -33.0% QoQ
150
-21.1% YoY 8.7% QoQ
0
-100.0% YoY -100.0% QoQ
80
-61.2% YoY inf% QoQ
2024 31
-77.5% YoY -61.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Aramchol search interestLast update: February 09 2024 06:29:46.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 06:29:49.

The average 5 years interest of Aramchol was 7.86 per week.
The last year interest of Aramchol compared to the last 5 years has changed by -18.96%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -8.48%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for non-alcoholic steato-hepatitis treatment to provide analysis

Correlation between past revenue and non-alcoholic steato-hepatitis treatment search interest

There is not enough data for non-alcoholic steato-hepatitis treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for non-alcoholic steato-hepatitis treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 06 2023 15:32:38.

After 34 days of this quarter the interest is at 141.0. Based on that we can calculate that during remaining 58 days it will total up to 382.0.
NASH therapy expected interest is significantly higher compared to previous quarter (+108.7%) and same quarter last year (+66.8%).

YearQ1Q2Q3Q4
2018 - - - 330
2019 196
-40.6% QoQ
375
91.3% QoQ
331
-11.7% QoQ
265
-19.7% YoY -19.9% QoQ
2020 376
91.8% YoY 41.9% QoQ
261
-30.4% YoY -30.6% QoQ
353
6.6% YoY 35.2% QoQ
281
6.0% YoY -20.4% QoQ
2021 304
-19.1% YoY 8.2% QoQ
308
18.0% YoY 1.3% QoQ
72
-79.6% YoY -76.6% QoQ
420
49.5% YoY 483.3% QoQ
2022 339
11.5% YoY -19.3% QoQ
216
-29.9% YoY -36.3% QoQ
234
225.0% YoY 8.3% QoQ
229
-45.5% YoY -2.1% QoQ
2023 388
14.5% YoY 69.4% QoQ
402
86.1% YoY 3.6% QoQ
183
-21.8% YoY -54.5% QoQ
141
-38.4% YoY -23.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and NASH therapy search interestLast update: November 06 2023 15:32:37.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 06 2023 15:32:38.

The average 5 years interest of NASH therapy was 23.09 per week.
The last year interest of NASH therapy compared to the last 5 years has changed by 3.68%.
The interest for NASH therapy is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by -5.67%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 06:29:54.

After 39 days of this quarter the interest is at 24.0. Based on that we can calculate that during remaining 52 days it will total up to 56.0.
liver diseases treatment expected interest is significantly lower compared to previous quarter (-73.3%) and same quarter last year (-68.2%).

YearQ1Q2Q3Q4
201936
129
258.3% QoQ
95
-26.4% QoQ
89
-6.3% QoQ
2020 116
222.2% YoY 30.3% QoQ
188
45.7% YoY 62.1% QoQ
76
-20.0% YoY -59.6% QoQ
111
24.7% YoY 46.1% QoQ
2021 166
43.1% YoY 49.5% QoQ
185
-1.6% YoY 11.4% QoQ
31
-59.2% YoY -83.2% QoQ
176
58.6% YoY 467.7% QoQ
2022 167
0.6% YoY -5.1% QoQ
143
-22.7% YoY -14.4% QoQ
104
235.5% YoY -27.3% QoQ
58
-67.0% YoY -44.2% QoQ
2023 176
5.4% YoY 203.4% QoQ
205
43.4% YoY 16.5% QoQ
118
13.5% YoY -42.4% QoQ
210
262.1% YoY 78.0% QoQ
2024 24
-86.4% YoY -88.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and liver diseases treatment search interestLast update: February 09 2024 06:29:54.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 06:29:56.

The average 5 years interest of liver diseases treatment was 9.97 per week.
The last year interest of liver diseases treatment compared to the last 5 years has changed by 26.58%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 41.16%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 09 2023 13:54:07.

After 34 days of this quarter the interest is at 14.0. Based on that we can calculate that during remaining 58 days it will total up to 38.0.
biopharmaceutical company expected interest is significantly lower compared to previous quarter (-57.8%) and same quarter last year (-72.5%).

YearQ1Q2Q3Q4
2018 - - - 127
2019 118
-7.1% QoQ
78
-33.9% QoQ
153
96.2% QoQ
205
61.4% YoY 34.0% QoQ
2020 101
-14.4% YoY -50.7% QoQ
226
189.7% YoY 123.8% QoQ
71
-53.6% YoY -68.6% QoQ
38
-81.5% YoY -46.5% QoQ
2021 84
-16.8% YoY 121.1% QoQ
188
-16.8% YoY 123.8% QoQ
58
-18.3% YoY -69.1% QoQ
87
128.9% YoY 50.0% QoQ
2022 170
102.4% YoY 95.4% QoQ
75
-60.1% YoY -55.9% QoQ
134
131.0% YoY 78.7% QoQ
138
58.6% YoY 3.0% QoQ
2023 118
-30.6% YoY -14.5% QoQ
54
-28.0% YoY -54.2% QoQ
90
-32.8% YoY 66.7% QoQ
14
-89.9% YoY -84.4% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and biopharmaceutical company search interestLast update: November 09 2023 13:54:06.
Correlation coefficient between keyword and revenue is 0.84
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 09 2023 13:54:07.

The average 5 years interest of biopharmaceutical company was 8.92 per week.
The last year interest of biopharmaceutical company compared to the last 5 years has changed by -26.91%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -43.79%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 06:29:59.

After 39 days of this quarter the interest is at 159.0. Based on that we can calculate that during remaining 52 days it will total up to 371.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019149
298
100.0% QoQ
256
-14.1% QoQ
356
39.1% QoQ
2020 172
15.4% YoY -51.7% QoQ
231
-22.5% YoY 34.3% QoQ
239
-6.6% YoY 3.5% QoQ
334
-6.2% YoY 39.7% QoQ
2021 298
73.3% YoY -10.8% QoQ
187
-19.0% YoY -37.2% QoQ
233
-2.5% YoY 24.6% QoQ
263
-21.3% YoY 12.9% QoQ
2022 403
35.2% YoY 53.2% QoQ
371
98.4% YoY -7.9% QoQ
282
21.0% YoY -24.0% QoQ
333
26.6% YoY 18.1% QoQ
2023 452
12.2% YoY 35.7% QoQ
459
23.7% YoY 1.5% QoQ
247
-12.4% YoY -46.2% QoQ
520
56.2% YoY 110.5% QoQ
2024 159
-64.8% YoY -69.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and overweight treatment search interestLast update: February 09 2024 06:29:59.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 06:30:00.

The average 5 years interest of overweight treatment was 23.92 per week.
The last year interest of overweight treatment compared to the last 5 years has changed by 37.0%.
The interest for overweight treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 45.52%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 18:14:25.

After 39 days of this quarter the interest is at 309.0. Based on that we can calculate that during remaining 52 days it will total up to 721.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019446
557
24.9% QoQ
536
-3.8% QoQ
543
1.3% QoQ
2020 618
38.6% YoY 13.8% QoQ
605
8.6% YoY -2.1% QoQ
575
7.3% YoY -5.0% QoQ
607
11.8% YoY 5.6% QoQ
2021 606
-1.9% YoY -0.2% QoQ
627
3.6% YoY 3.5% QoQ
564
-1.9% YoY -10.0% QoQ
613
1.0% YoY 8.7% QoQ
2022 829
36.8% YoY 35.2% QoQ
753
20.1% YoY -9.2% QoQ
689
22.2% YoY -8.5% QoQ
799
30.3% YoY 16.0% QoQ
2023 867
4.6% YoY 8.5% QoQ
837
11.2% YoY -3.5% QoQ
749
8.7% YoY -10.5% QoQ
907
13.5% YoY 21.1% QoQ
2024 309
-64.4% YoY -65.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and obesity treatment search interestLast update: February 09 2024 18:14:25.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 18:14:26.

The average 5 years interest of obesity treatment was 52.25 per week.
The last year interest of obesity treatment compared to the last 5 years has changed by 21.78%.
The interest for obesity treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 43.38%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for pre-diabetic treatment to provide analysis

Correlation between past revenue and pre-diabetic treatment search interest

There is not enough data for pre-diabetic treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for pre-diabetic treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for type-II-diabetes mellitus therapy to provide analysis

Correlation between past revenue and type-II-diabetes mellitus therapy search interest

There is not enough data for type-II-diabetes mellitus therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for type-II-diabetes mellitus therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for GLMD
Earnings date: 2024-03-27 After close
Company name: Galmed Pharmaceuticals Ltd
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T07:30:00-04:00

PR Newswire
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

2026-05-14T05:00:00.000Z

US FDA
Tentative Approval of Finerenone, Anda #220747 (Labeling)

2026-05-06T07:30:00-04:00

PR Newswire
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

2026-04-20T05:00:00.000Z

US FDA
Tentative Approval of Vericiguat, Anda #220221

2026-04-14T07:30:00-04:00

PR Newswire
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

2026-04-09T07:30:00-04:00

PR Newswire
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

2026-03-31T16:15:00-04:00

PR Newswire
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

2026-03-23T05:00:00.000Z

US FDA
Tentative Approval of Ruxolitinib, Anda #220375

2026-01-30T16:15:00-05:00

PR Newswire
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

2025-12-09T00:00:00.000Z

US Patent Trial and Appeal Board
Alcon Pharmaceuticals Ltd. - Appeal, Affirmed

2025-12-08T08:30:00-05:00

PR Newswire
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

2025-12-04T08:30:00-05:00

PR Newswire
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

2025-12-01T08:30:00-05:00

PR Newswire
Galmed Issues CEO Letter to Shareholders

2025-11-26T08:30:00-05:00

PR Newswire
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-18T08:30:00-05:00

PR Newswire
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine